Breakthrough Pace Shows No Signs Of Slowing
Executive Summary
FDA started off 2016 with a spate of new breakthrough therapy designations, feeding the popular program – and fueling agency concerns about workforce strain.
You may also be interested in...
Keeping Track: FDA's Review Actions Carry On During Shutdown
The latest drug development news and highlights from our US FDA Performance Tracker.
Catalyst Stumbles With Filing Of Controversial 'Breakthrough Therapy' Firdapse
FDA’s refuse-to-file letter for Firdapse in two ultra-rare neuromuscular disorders does not make judgments about the drug’s safety or efficacy, says Catalyst.
US FDA’s Median Review Time For Novel Drugs Held Steady In 2020
Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: